Precision Biosciences Stock Today
| DTIL Stock | USD 4.81 0.05 1.03% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Precision BioSciences is selling for 4.81 as of the 23rd of July 2025. This is a 1.03 percent decrease since the beginning of the trading day. The stock's lowest day price was 4.81. Precision BioSciences has more than 60 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 24th of April 2025 and ending today, the 23rd of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of March 2019 | Category Healthcare | Classification Health Care |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. The company has 11.09 M outstanding shares of which 1.3 M shares are currently shorted by private and institutional investors with about 2.56 trading days to cover. More on Precision BioSciences
Moving against Precision Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Precision Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Michael Amoroso | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPrecision BioSciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Precision BioSciences' financial leverage. It provides some insight into what part of Precision BioSciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Precision BioSciences (DTIL) is traded on NASDAQ Exchange in USA. It is located in 302 East Pettigrew St., Durham, NC, United States, 27701 and employs 107 people. Precision BioSciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 53.89 M. Precision BioSciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 11.09 M outstanding shares of which 1.3 M shares are currently shorted by private and institutional investors with about 2.56 trading days to cover.
Precision BioSciences currently holds about 184.14 M in cash with (58.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66.
Check Precision BioSciences Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Precision BioSciences is $53.89 Million. 30% of Precision BioSciences outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the company is less than the current market value, you may not be able generate positive returns on investment in the long run.
Check Precision Ownership Details
Precision Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2025-03-31 | 54.8 K | |
| Dimensional Fund Advisors, Inc. | 2025-03-31 | 53.6 K | |
| Northern Trust Corp | 2025-03-31 | 43 K | |
| Moloney Securities Asset Management | 2025-03-31 | 42.9 K | |
| Royal Bank Of Canada | 2025-03-31 | 40 K | |
| Commonwealth Equity Services Inc | 2025-03-31 | 37.2 K | |
| State Street Corp | 2025-03-31 | 22 K | |
| Two Sigma Investments Llc | 2025-03-31 | 13.6 K | |
| Morgan Stanley - Brokerage Accounts | 2025-03-31 | 12.3 K | |
| Aquilo Capital Management, Llc | 2025-03-31 | 726.1 K | |
| Tang Capital Management Llc | 2025-03-31 | 673.3 K |
Precision BioSciences Historical Income Statement
Precision Stock Against Markets
Precision BioSciences Corporate Management
| Maurissa Messier | Senior Communications | Profile | |
| Fayaz Khazi | Chief Systems | Profile | |
| Derek Jantz | Chief CoFounder | Profile | |
| Jefferson Smith | CoFounder Officer | Profile | |
| Cassie Gorsuch | Chief Officer | Profile | |
| Bruce Stevens | Vice Compliance | Profile | |
| John Kelly | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.